Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
Assessment of Birth Outcomes in Eswatini After Transition to Dolutegravir-based Treatment
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens. The main question the study aims to answer is, what is the proportion of neural tube defects among live and stillborn infants delivered by:
- HIV-positive women on DTG at conception
- HIV-negative women
- HIV-positive women on non-DTG ARV at conception
Participants will be interviewed for information on HIV testing and antiretroviral therapy history, other medical history of selected conditions (e.g., diabetes, malaria, TB) and potential birth defect exposures. Photographs will be taken of the infants. Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) will be collected from patient records.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Michelle Gill, PhD
- Phone Number: +1 2024488403
- Email: mgill@pedaids.org
Study Contact Backup
- Name: Caspian Chouraya, MD
- Phone Number: +268 24041811
- Email: cchouraya@pedaids.org
Study Locations
-
-
-
Manzini, Eswatini
- Raleigh Fitkin Memorial Hospital
-
Manzini, Eswatini
- Mankayane Government Hospital
-
Mbabane, Eswatini
- Mbabane Government Hospital
-
-
Lubombo Region
-
Siteki, Lubombo Region, Eswatini
- Good Shepherd Hospital
-
-
Shiselweni
-
Hlatikulu, Shiselweni, Eswatini
- Hlathikhulu Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Surveillance component includes all deliveries/admissions as defined in study population description. For a subset of the population recruited for additional data collection:
Inclusion Criteria:
- women whose live or stillborn infant has birth defect as identified by a midwife or other clinician at the study hospital
- willing to provide informed consent
Exclusion Criteria:
- unable to provide informed consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
HIV-positive DTG preconception
HIV status defined as a documented positive result in the perinatal and/or maternity register or other clinical source record.
Preconception drug exposure determined using date of DTG initiation and LMP date or gestational age at delivery (if LMP not available).
ART at conception is defined as maternal ART that started up to 8 weeks after the calculated LMP date, which would be up to 6 weeks after the estimated date of conception.
As this is the group of interest, sample size target was determined as 10,000.
|
|
HIV-negative
Women with the last HIV test result recorded during pregnancy or labor and delivery as negative.
|
|
HIV-positive on non-DTG ARV preconception
HIV status defined as a documented positive result in the perinatal and/or maternity register or other clinical source record.
Preconception drug exposure determined using date of ARV initiation (e.g., efavirenz) and LMP date or gestational age at delivery (if LMP not available).
ART at conception is defined as maternal ART that started up to 8 weeks after the calculated LMP date, which would be up to 6 weeks after the estimated date of conception.
Other groups to be included as informed by the data (e.g., HIV+ not on ART a conception, unknown ART at conception, etc).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on DTG at conception.
Time Frame: 24 months
|
Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on DTG at conception
|
24 months
|
|
Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-negative women
Time Frame: 24 months
|
Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-negative women
|
24 months
|
|
Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on non-DTG ARV at conception
Time Frame: 24 months
|
Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on non-DTG ARV at conception
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of major external birth defects among all live and stillborn infants regardless of maternal HIV or ART status.
Time Frame: 24 months
|
Number of live and stillborn infants with major external birth defects divided by the total number of live and stillborn infants among all women regardless of HIV or ART status
|
24 months
|
|
Proportion of other pregnancy outcomes
Time Frame: 24 months
|
Number of live and stillborn infants with low birthweight and pre-term delivery divided by the total number of live infants among women (overall and by HIV/ART status); number of stillborn infants among all pregnancies, including miscarriages
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Michelle Gill, PhD, Elizabeth Glaser Pediatric AIDS Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EG0259
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.